pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Iambic Therapeutics Inc

updated 2mo ago
Website ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 1: 1
1Phase 1
Phase 1
IAM-1363
Bladder Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Iambic Therapeutics Inc jobs →

News

  • ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
    Two RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of the IPO frenzy, which has led to a total of 27 newly public biotechs so far this year.
    biospace · 8d ago
  • RNAi drug specialist ADARx raises $446M IPO
    ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.
    biopharma_dive · 9d ago
  • Nvidia-backed AI biotech Iambic Therapeutics files for IPO
    Iambic Therapeutics has filed to go public, the latest example in the maturation of the next crop of AI-focused biotech startups. The San Diego-based company disclosed new details on its own pipeli…
    endpoints · 11d ago
  • 2026 IPO blitz continues with 4 new biotech filings
    With more than 25 companies debuting on the public markets, 2026 has recorded the highest number of biotech IPOs since 2021. Now, four companies—including Iambic Therapeutics and ADARx Pharmaceutic…
    biospace · 11d ago
  • Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
    Iambic Therapeutics is maintaining the momentum generated by its recent mega round and Big Pharma partnerships by gearing up to go public.
    fiercebiotech · 12d ago
  • Iambic signs AbbVie deal, releases next generation of Enchant model
    Iambic Therapeutics released the next generation of one of its main AI models, while signing an R&D partnership with AbbVie. Founded in 2019, the San Diego-based biotech has become a leading startu…
    endpoints · 12d ago
  • Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
    The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."
    biopharma_dive · 17d ago
identifiers
source
globaldata
top tags
Colorectal Cancer1NSCLC1Oncology1
mentioned in
7news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?